Compare BTBT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | PRTC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 464.3M |
| IPO Year | 2017 | N/A |
| Metric | BTBT | PRTC |
|---|---|---|
| Price | $1.67 | $16.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 18.3M | 4.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 218.75 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $108,050,720.00 | N/A |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $90.95 | N/A |
| P/E Ratio | ★ $3.65 | $8.09 |
| Revenue Growth | ★ 140.56 | N/A |
| 52 Week Low | $1.49 | $13.30 |
| 52 Week High | $4.55 | $20.00 |
| Indicator | BTBT | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 41.11 |
| Support Level | $1.53 | $15.72 |
| Resistance Level | $2.43 | $18.10 |
| Average True Range (ATR) | 0.11 | 0.50 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 29.69 | 8.09 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.